Browsing by Author "Acevedo, Johanna"

Now showing 1 - 15 of 15
  • Thumbnail Image
    Item
    Arsenic methylation and lung and bladder cancer in a case-control study in northern Chile
    (2014) Melak, Dawit; Ferreccio Readi, Catterina; Kalman, David; Parra, Roxana; Acevedo, Johanna; Pérez, Liliana; Cortés Arancibia, Sandra; Smith, Allan H.; Yuan, Yan; Liaw, Jane
  • Thumbnail Image
    Item
    Arsenic, Tobacco Smoke, and Occupation Associations of Multiple Agents with Lung and Bladder Cancer
    (2013) Ferreccio Readi, Catterina; Yuan, Yan; Calle, Jacqueline; Benítez, Hugo; Parra, Roxana L.; Acevedo, Johanna; Smith, Allan H.; Liaw, Jane; Steinmaus, Craig
  • Thumbnail Image
    Item
    Case-Control Study of Arsenic in Drinking Water and Kidney Cancer in Uniquely Exposed Northern Chile
    (2013) Ferreccio Readi, Catterina; Smith, Allan H.; Durán, Viviana; Barlaro, Teresa; Benítez, Hugo; Valdés, Rodrigo O.; Aguirre, Juan José; Moore, Lee E.; Acevedo, Johanna; Vásquez, María Isabel; Pérez, Liliana; Yuan, Yan; Liaw, Jane; Cantor, Kenneth P.; Steinmaus, Craig
  • Thumbnail Image
    Item
    Chile's National Advisory Committee on Immunization (CAVEI) : Evidence-based recommendations for public policy decision-making on vaccines and immunization
    (2019) Dabanch, Jeannette; González, Cecilia; Cerda, Jaime; Acevedo, Johanna; Calvo, Mario; Díaz, Eduardo; Endeiza, María; Inostroza, Jaime; Rodríguez, Jaime; Saldaña, Adiela; Santillana, Solange; El Omeiri, Nathalie; Bastías, Magdalena
  • Thumbnail Image
    Item
    Differential Effects of a Telemonitoring Platform in the Development of Chemotherapy-Associated Toxicity: A Randomized Trial Protocol
    (2024) Martínez, Felipe; Taramasco, Carla; Espinoza Sepúlveda, Manuel Antonio; Acevedo, Johanna; Goic Boroevic, Carolina; Nervi Nattero, Bruno
    Chemotherapy requires careful monitoring, but traditional follow-up approaches face significant challenges that were highlighted by the COVID-19 pandemic. Hence, exploration into telemonitoring as an alternative emerged. The objective is to assess the impact of a telemonitoring platform that provides clinical data to physicians overseeing solid tumor patients, aiming to enhance the care experience. The methodology outlines a parallel-group randomized clinical trial involving recently diagnosed patients with solid carcinomas preparing for curative intent chemotherapy. Eligible adult patients diagnosed with specific carcinoma types and proficient in Spanish, possessing smartphones, will be invited to participate. They will be randomized using concealed allocation sequences into two groups: one utilizing a specialized smartphone application called Contigo for monitoring chemotherapy toxicity symptoms and accessing educational content, while the other receives standard care. Primary outcome assessment involves patient experience during chemotherapy using a standardized questionnaire. Secondary outcomes include evaluating severe chemotherapy-associated toxicity, assessing quality of life, and determining user satisfaction with the application. The research will adhere to intention-to-treat principles. This study has been registered at ClinicalTrials.gov (NCT06077123)
  • Thumbnail Image
    Item
    Distribution of dysplasia and cancer in the gallbladder : an analysis from a high cancer-risk population
    (2018) Koshiol, Jill; Bellolio, Enrique; Vivallo, Carolina; Cook, María Paz; McGee, Emma E.; Losada, Héctor; Van Dyke, Alison L.; Van De Wyngard, Vanessa; Prado, Rodrigo; Villaseca, Miguel; Riquelme, Pía; Acevedo, Johanna; Olivo, Vanessa; Pettit, Karen; Hildesheim, Allan; Medina, Karie; Memis, Bahar; Adsay, Volkan; Ferreccio Readi, Catterina; Araya, Juan Carlos
  • Thumbnail Image
    Item
    Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study
    (ELSEVIER, 2023) Jara, Alejandro; Undurraga, Eduardo A.; Flores, Juan Carlos; Zubizarreta, Jose R.; Gonzalez, Cecilia; Pizarro, Alejandra; Ortuno-Borroto, Duniel; Acevedo, Johanna; Leo, Katherinne; Paredes, Fabio; Bralic, Tomas; Vergara, Veronica; Leon, Francisco; Parot, Ignacio; Leighton, Paulina; Suarez, Pamela; Rios, Juan Carlos; Garcia-Escorza, Heriberto; Araos, Rafael
    Background Policymakers urgently need evidence to adequately balance the costs and benefits of mass vaccination against COVID-19 across all age groups, including children and adolescents. In this study, we aim to assess the effectiveness of CoronaVac's primary series among children and adolescents in Chile. Methods We used a large prospective national cohort of about two million children and adolescents 6-16 years to estimate the effectiveness of an inactivated SARS-CoV-2 vaccine (CoronaVac) in preventing laboratory-confirmed symptomatic SARS-CoV-2 infection (COVID-19), hospitalisation, and admission to an intensive care unit (ICU) associated with COVID-19. We compared the risk of individuals treated with a complete primary immunization schedule (two doses, 28 days apart) with the risk of unvaccinated individuals during the follow-up period. The study was conducted in Chile from June 27, 2021, to January 12, 2022, when the SARS-CoV-2 Delta variant was predominant but other variants of concern were co-circulating, including Omicron. We used inverse probability-weighted survival regression models to estimate hazard ratios of complete immunization over the unvaccinated status, accounting for time-varying vaccination exposure and adjusting for relevant demographic, socioeconomic, and clinical confounders.Findings The estimated adjusted vaccine effectiveness for the inactivated SARS-CoV-2 vaccine in children aged 6-16 years was 74.5% (95% CI, 73.8-75.2), 91.0% (95% CI, 87.8-93.4), 93.8% (95% CI, 87.8-93.4) for the prevention of COVID-19, hospitalisation, and ICU admission, respectively. For the subgroup of children 6-11 years, the vaccine effectiveness was 75.8% (95% CI, 74.7-76.8) for the prevention of COVID-19 and 77.9% (95% CI, 61.5-87.3) for the prevention of hospitalisation.Interpretation Our results suggest that a complete primary immunization schedule with the inactivated SARS-CoV-2 vaccine provides effective protection against severe COVID-19 disease for children 6-16 years.Copyright & COPY; 2023 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
  • Thumbnail Image
    Item
    Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
    (MASSACHUSETTS MEDICAL SOC, 2021) Jara, Alejandro; Undurraga, Eduardo A.; Gonzalez, Cecilia; Paredes, Fabio; Fontecilla, Tomas; Jara, Gonzalo; Pizarro, Alejandra; Acevedo, Johanna; Leo, Katherine; Leon, Francisco; Sans, Carlos; Leighton, Paulina; Suarez, Pamela; Garcia Escorza, Heriberto; Araos, Rafael
    Inactivated SARS-CoV-2 Vaccine in Chile In a national prospective cohort study involving 10.2 million participants in Chile, the effectiveness of an inactivated SARS-CoV-2 vaccine, which had been developed in China and administered in two doses 28 days apart, was estimated. Effectiveness among fully immunized persons was estimated at 65.9% for Covid-19 and at 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.
  • Thumbnail Image
    Item
    Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile
    (NATURE PORTFOLIO, 2022) Jara, Alejandro; Undurraga, Eduardo A.; Zubizarreta, Jose R.; Gonzalez, Cecilia; Acevedo, Johanna; Pizarro, Alejandra; Vergara, Veronica; Soto-Marchant, Mario; Gilabert, Rosario; Flores, Juan Carlos; Suarez, Pamela; Leighton, Paulina; Eguiguren, Pablo; Carlos Rios, Juan; Fernandez, Jorge; Garcia-Escorza, Heriberto; Araos, Rafael
    The outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3-5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac's inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5-39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6-75.2) against hospitalization and 69.0% (95% CI, 18.6-88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3-5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.
  • Thumbnail Image
    Item
    Effects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE) A Randomized Trial Protocol
    (2024) Martínez, Felipe; Taramasco Toro, Carla; Espinoza Sepúlveda, Manuel Antonio; Acevedo, Johanna; Goic Boroevic, Carolina; Nervi Nattero, Bruno
    Cancer, a pervasive global health challenge, necessitates chemotherapy or radiotherapy treatments for many prevalent forms. However, traditional follow-up approaches encounter limitations, exacerbated by the recent COVID-19 pandemic. Consequently, telemonitoring has emerged as a promising solution, although its clinical implementation lacks comprehensive evidence. This report depicts the methodology of a randomized trial which aims to investigate whether leveraging a smartphone app called Contigo for disease monitoring enhances self-reported quality of life among patients with various solid cancers compared to standard care. Secondary objectives encompass evaluating the app’s impact on depressive symptoms and assessing adherence to in-person appointments. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients’ progress and providing educational content to assist patients in managing common clinical situations related to their disease. The study will assess outcomes such as quality of life changes and depressive symptom development using validated scales, and adherence to in-person appointments. Specific scales include the EuroQol Group’s EQ-5D questionnaire and the Patient Health Questionnaire (PHQ-9). We hypothesize that the use of Contigo will assist and empower patients receiving cancer treatment, which will translate to better quality of life scores and a reduced incidence of depressive symptoms. All analyses will be undertaken with the intention-to-treat principle by a statistician unaware of treatment allocation. This trial is registered in ClinicalTrials under the registration number NCT06086990
  • Thumbnail Image
    Item
    Elevated Lung Cancer in Younger Adults and Low Concentrations of Arsenic in Water
    (2014) Steinmaus, Craig; Ferreccio Readi, Catterina; Yuan, Yan; Acevedo, Johanna; González, Francisca; Pérez, Liliana; Cortés Arancibia, Sandra; Balmes, John R.; Liaw, Jane; Smith, Allan H.
  • Thumbnail Image
    Item
    High Burden of Intestinal Colonization With Antimicrobial-Resistant Bacteria in Chile: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study
    (2023) Araos, Rafael; Smith, Rachel M.; Styczynski, Ashley; Sánchez Barría, Felipe Andrés; Acevedo, Johanna; Maureira, Lea; Paredes, Catalina; Gonzalez, Maite; Rivas, Lina; Spencer-Sandino, Maria; Peters, Anne; Khan, Ayesha; Sepulveda, Dino; Rojas Wettig, Loreto; Rioseco, Maria Luisa; Usedo, Pedro; Rojas Soto, Pamela; Huidobro, Laura Andrea; Ferreccio Readi, Catterina; Park, Benjamin J.; Undurraga Fourcade, Eduardo Andrés; D'Agata, Erika M. C.; Jara Vallejos, Alejandro Antonio; Munita, Jose M.
    We report a high colonization burden resulting from antimicrobial-resistant Gram-negative bacteria in hospitals and a community in Chile. Strikingly, 29% (95% confidence interval, 24-34) of community-dwelling adults carried extended-spectrum cephalosporin-resistant Enterobacterales, highlighting the magnitude of the community reservoir of antimicrobial resistance., Background Antimicrobial resistance is a global threat, heavily impacting low- and middle-income countries. This study estimated antimicrobial-resistant gram-negative bacteria (GNB) fecal colonization prevalence in hospitalized and community-dwelling adults in Chile before the coronavirus disease 2019 pandemic. Methods From December 2018 to May 2019, we enrolled hospitalized adults in 4 public hospitals and community dwellers from central Chile, who provided fecal specimens and epidemiological information. Samples were plated onto MacConkey agar with ciprofloxacin or ceftazidime added. All recovered morphotypes were identified and characterized according to the following phenotypes: fluoroquinolone-resistant (FQR), extended-spectrum cephalosporin-resistant (ESCR), carbapenem-resistant (CR), or multidrug-resistant (MDR; as per Centers for Disease Control and Prevention criteria) GNB. Categories were not mutually exclusive. Results A total of 775 hospitalized adults and 357 community dwellers were enrolled. Among hospitalized subjects, the prevalence of colonization with FQR, ESCR, CR, or MDR-GNB was 46.4% (95% confidence interval [CI], 42.9-50.0), 41.2% (95% CI, 37.7-44.6), 14.5% (95% CI, 12.0-16.9), and 26.3% (95% CI, 23.2-29.4). In the community, the prevalence of FQR, ESCR, CR, and MDR-GNB colonization was 39.5% (95% CI, 34.4-44.6), 28.9% (95% CI, 24.2-33.6), 5.6% (95% CI, 3.2-8.0), and 4.8% (95% CI, 2.6-7.0), respectively. Conclusions A high burden of antimicrobial-resistant GNB colonization was observed in this sample of hospitalized and community-dwelling adults, suggesting that the community is a relevant source of antibiotic resistance. Efforts are needed to understand the relatedness between resistant strains circulating in the community and hospitals.
  • Thumbnail Image
    Item
    Obesity and increased susceptibility to arsenic-related type 2 diabetes in northern Chile
    (2018) Castriota, Felicia; Acevedo, Johanna; Ferreccio Readi, Catterina; Smith, Allan H.; Liaw, Jane; Smith, Martyn T.; Steinmaus, Craig
  • Thumbnail Image
    Item
    Salmonella enterica serovar Typhi and gallbladder cancer : a case control study and meta-analysis
    (2016) Koshiol, Jill; Wozniak Banchero, Aniela; Cook, María Paz; Adaniel, Christina; Acevedo, Johanna; Azócar, Lorena; Roa Strauch, Juan Carlos Enrique; Miquel P., Juan Francisco; Ferreccio Readi, Catterina; Díaz, Alfonso; Molina, Héctor; Miranda, Carolina; Castillo, Claudia
  • Thumbnail Image
    Item
    The impact of BMI on non-malignant respiratory symptoms and lung function in arsenic exposed adults of Northern Chile
    (2017) Nardone, Anthony; Ferreccio Readi, Catterina; Acevedo, Johanna; Enanoria, Wayne; Blair, Alden; Smith, Allan H.; Balmes, John; Steinmaus, Craig